APA (7th ed.) Citation

CALDERON, B., MULLINS, G. R., HODSDON, M., LI, G., ANGLIN, G., URVA, S., . . . BROWN, K. (2022). 742-P: Antidrug Antibodies Do Not Impact Pharmacokinetics, Efficacy, and Safety of Tirzepatide: Analysis of Data from 7 Phase 3 Studies. Diabetes (New York, N.Y.), 71(Supplement_1), . https://doi.org/10.2337/db22-742-P

Chicago Style (17th ed.) Citation

CALDERON, BORIS, et al. "742-P: Antidrug Antibodies Do Not Impact Pharmacokinetics, Efficacy, and Safety of Tirzepatide: Analysis of Data from 7 Phase 3 Studies." Diabetes (New York, N.Y.) 71, no. Supplement_1 (2022). https://doi.org/10.2337/db22-742-P.

MLA (9th ed.) Citation

CALDERON, BORIS, et al. "742-P: Antidrug Antibodies Do Not Impact Pharmacokinetics, Efficacy, and Safety of Tirzepatide: Analysis of Data from 7 Phase 3 Studies." Diabetes (New York, N.Y.), vol. 71, no. Supplement_1, 2022, https://doi.org/10.2337/db22-742-P.